N-terminal-acetylases (NATs) catalyse the covalent attachment of an acetyl moiety from acetyl-CoA to the free alpha-amino group at the N-terminus of a protein. This irreversible modification neutralizes the positive charge at the N-terminus and makes the N-terminal residue larger and more hydrophobic, and may also play a role in membrane targeting and gene silencing. The NatC complex is found in all eukaryotic organisms, and specifically targets N-terminal L-methionine residues attached to bulky hydrophobic residues at the second position, including Leu, Ile, Phe, Trp, and Tyr residues.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
SYSTEMATIC NAME
IUBMB Comments
acetyl-CoA:N-terminal-Met-Leu/Ile/Phe/Trp/Tyr-[protein] Met Nalpha-acetyltransferase
N-terminal-acetylases (NATs) catalyse the covalent attachment of an acetyl moiety from acetyl-CoA to the free alpha-amino group at the N-terminus of a protein. This irreversible modification neutralizes the positive charge at the N-terminus and makes the N-terminal residue larger and more hydrophobic, and may also play a role in membrane targeting and gene silencing. The NatC complex is found in all eukaryotic organisms, and specifically targets N-terminal L-methionine residues attached to bulky hydrophobic residues at the second position, including Leu, Ile, Phe, Trp, and Tyr residues.
almost no activity with nuclear factor kappaB p65 (MDELFPLRWGRPVGRRRRPVRVYP), kinesin KIF4A (MKEEVKGRWGRPVGRRRRPVRVYP), and high-mobility group protein A1 (SESSSKSRWGRPVGRRRRPVRVYP)
full-length Naa30 acetylates a classical NatC substrate peptide in vitro, whereas no significant NAT activity is detected for Naa3028. Neither full-length Naa30 nor Naa30288 display any lysine acetyltransferase activity, and neither Naa30 isoforms have KAT activity towards histones. The SESSS, EEEIA and MDELF peptides are negative controls and represent NatA, Naa10 and NatB substrates, respectively. Poor activity with SGRGK peptide, which contains the natural 28-mer N-terminal sequence of histone H4, and represents a NatD-type substrate
full-length Naa30 acetylates a classical NatC substrate peptide in vitro, whereas no significant NAT activity is detected for Naa3028. Neither full-length Naa30 nor Naa30288 display any lysine acetyltransferase activity, and neither Naa30 isoforms have KAT activity towards histones. The SESSS, EEEIA and MDELF peptides are negative controls and represent NatA, Naa10 and NatB substrates, respectively. Poor activity with SGRGK peptide, which contains the natural 28-mer N-terminal sequence of histone H4, and represents a NatD-type substrate
almost no activity with nuclear factor kappaB p65 (MDELFPLRWGRPVGRRRRPVRVYP), kinesin KIF4A (MKEEVKGRWGRPVGRRRRPVRVYP), and high-mobility group protein A1 (SESSSKSRWGRPVGRRRRPVRVYP)
A genome-wide approach to link genotype to clinical outcome by utilizing next generation sequencing and gene chip data of 6,697 breast cancer patients.
enzyme Naa30 belongs to the GNAT superfamily of acetyltransferases characterized by the highly conserved GNAT fold, which promotes Ac-CoA binding and substrate recognition
depletion of the human N-terminal acetyltransferase hNaa30 disrupts Golgi integrity and Golgi-associated GTPase ADP ribosylation factor related protein 1 (ARFRP1) localization. Depletion of the hNatC catalytic subunit hNaa30 leads to disassembly of the Golgi apparatus and trans-Golgi network (TGN). ARFRP1 shifts from a predominantly cis-Golgi and TGN localization to localizing both Golgi and non-Golgi vesicular structures in hNaa30-depleted cells (smaller vesicle-like membranous compartments). Loss of membrane association of ARFRP1 is not observed. hNaa30 depletion induces Golgi scattering and induces aberrant ARFRP1 Golgi localization. Knockdown of each of the hNatC subunits in HeLa cells leads to p53-dependent apoptosis. Naa30 depletion severely disrupts mitochondrial organization. Knockdown phenotypes are specific for hNaa30 depletion and not a result of si-hNAA30-independent effects. Phenotypes, detailed overview
overexpression of full-length Naa30 increases cell viability via inhibition of apoptosis. In contrast, Naa30288 does not exert an anti-apoptotic effect
the human NatC complex (hNatC) is an evolutionarily conserved complex composed of the catalytic subunit hNaa30 (hMak3) and the auxiliary subunits hNaa35 (hMak10) and hNaa38 (hMak31). NatC Nt-acetylates Met-Leu-, Met-Ile-, Met-Phe-, Met-Trp-, Met-Val-, Met-Met-, Met-His-, and Met-Lys-N-termini. The NatC complex is one of several Nt-acetyltransferases (NATs) that perform Nt-acetylation in eukaryotes. Nt-acetylation or protein N-alpha-terminal acetylation, is the addition of an acetyl group on the Nalpha-amino group of proteins. It is one of the most abundant protein modifications in eukaryotes and displays a wide array of biological functions. The Golgi apparatus associated GTPase ADP ribosylation factor related protein 1 (ARFRP1) requires N-terminal acetylation for membrane association and based on its N-terminal sequence, it is likely to be a substrate of hNaa30. ARFRP1 is involved in endosome-to-trans-Golgi network (TGN) traffic
the NatC complex consists of the catalytic subunit Naa30 and the auxiliary subunits Naa35 and Naa38, and can potentially Nt-acetylate cytoplasmic proteins when the initiator methionine is followed by a bulky hydrophobic/amphipathic residue at position 2. Full-length enzyme Naa30362 improves cell viability and inhibits apoptosis
identification of a splice variant of human NAA30, which encodes a truncated protein named Naa30288. DNA sequencing reveals that the 900 bp product derived from alternative splicing results in a 222 bp deletion from the 3' end of exon 1 (c.550_771del). The truncated splice variant (867 bp) is otherwise identical to NAA30. Splicing NAA30_v2 translates into a truncated isoform (p.Val184_Leu257del) consisting of 288 amino acids (Naa30288). The splice variant is abundantly present in thyroid cancer tissues and in several different human cancer cell lines. Naa30288 localizes predominantly to the nucleus, as opposed to annotated Naa30 which has a cytoplasmic localization. Naa30288 is missing elements of the GNAT fold. Full-length Naa30 acetylates the classical NatC substrate peptide MLGTG in vitro, whereas no significant NAT activity is detected for Naa3028. Naa30288 appears to be enzymatically inactive. Overexpression of full-length Naa30362 increases cell viability via inhibition of apoptosis. In contrast, Naa30288 does not exert an anti-apoptotic effect
identification of a splice variant of human NAA30, which encodes a truncated protein named Naa30288. DNA sequencing reveals that the 900 bp product derived from alternative splicing results in a 222 bp deletion from the 3' end of exon 1 (c.550_771del). The truncated splice variant (867 bp) is otherwise identical to NAA30. Splicing NAA30_v2 translates into a truncated isoform (p.Val184_Leu257del) consisting of 288 amino acids (Naa30288). The splice variant is abundantly present in thyroid cancer tissues and in several different human cancer cell lines. Naa30288 localizes predominantly to the nucleus, as opposed to annotated Naa30 which has a cytoplasmic localization. Naa30288 is missing elements of the GNAT fold. Full-length Naa30 acetylates the classical NatC substrate peptide MLGTG in vitro, whereas no significant NAT activity is detected for Naa3028. Naa30288 appears to be enzymatically inactive. Overexpression of full-length Naa30362 increases cell viability via inhibition of apoptosis. In contrast, Naa30288 does not exert an anti-apoptotic effect
gene NAA30, DNA and amino acid sequence, analysis and comparison, alternative splicing variants NAA30_v1 (Naa30362) and NAA30_v2 (Naa30288), cloning from HeLa cells, overexpression of MBP-tagged Naa30362-V5 and Naa30288-V5 in HeLa cells